Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Human Genome Sciences Inc. Updates Albuferon Data

May 3, 2006

On Monday, Human Genome Sciences Inc. said a mid-stage drug trial of patients who had been previously treated for hepatitis C found that its candidate Albuferon, in combination with ribavirin, reduced the virus to undetectable levels in 31 percent (22 of 71 patients) of patients treated for 48 weeks. Twelve weeks after treatment ended, 20 percent (14 patients) maintained undetectable levels of virus. HGS plans to enter more advanced clinical trials by the end of this year.

Back to other news for May 3, 2006

Adapted from:
Associated Press
05.01.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement